References
- Lee A. W.M., Law S. C.K., Ng S. H., et al. Retrospective analysis of nasopharyngeal carcinoma treated during 1976–1985: late complications following megavoltage irradiation. Br. J. Radiol. 1992; 65: 918–928, [PUBMED], [INFOTRIEVE]
- Altun M., Fandi A., Dupuis O., et al. Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects. Int. J. Radiat. Oncol. Biol. Phys. 1995; 32: 859–877, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Al-Sarraf M., LeBlanc M., Shanker Giri P. G., et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopaharyngeal cancer: phase III randomized intergroup study 0099. J. Clin. Oncol. 1998; 16: 1310–1317
- Perez C. A., Venkata R. D., Marcial-Vega V., et al. Carcinoma of the nasopharynx: factors affecting prognosis. Int. J. Radiat. Oncol. Biol. Phys. 1992; 23: 271–280, [PUBMED], [INFOTRIEVE]
- Roychowdhury D. F., Tseng A., Jr., Fu K. K., et al. New prognostic factors in nasopharyngeal carcinoma: tumor angiogenesis and C-erbB2 expression. Cancer 1996; 77: 1419–1426, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Klein G. The relationship of the virus to nasopharyngeal carcinoma. The Epstein-Barr Virus, M. A. Epstein, B. G. Aching. Springer, New York 1979; 340–350
- Elliott K. Epstein-Barr virus-increasing evidence of a link to carcinoma. N. Engl. J. Med. 1995; 333: 724–726, [CROSSREF], [CSA]
- Young L. S., Dawson C., Clark D., et al. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J. Gen. Virol. 1988; 69: 1051–1065, [PUBMED], [INFOTRIEVE], [CSA]
- Hu L. F., Zhen Q. F., Zhang Y. W., et al. Differences in the growth pattern and clinical course of EBV-LMP1 expressing and nonexpressing nasopharyngeal carcinoma. Eur. J. Cancer 1995; 31: 658–660, [CROSSREF]
- Horikawa T., Yoshizaki T., Sheen T.-S., et al. Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma. Cancer 2000; 89: 715–723, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Zlotnik A., Moore K. W. Interleukine-10. Cytokine 1991; 3: 366–371, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Hus D. H., De Waal Malefyt R., Fiorentino D. F., et al. Expression of IL-10 activity by Ebstein Barr virus BCRF1. Science 1990; 250: 830–832
- Matsuda M., Salazar F., Petersson M., et al. IL-10 pre-treatment protects target cells from tumor and allo-specýfýc cytotoxic T cells and down regulates HLA-class I expression. J. Exp. Med. 1994; 180: 2371–2376, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Nakagomi H., Dolcetti R., Bejarano T., et al. The Ebstein Barr virus latent membrane protein-1 (LMP1) induces IL-10 in Burkitt-lymphoma lines. Int. J. Cancer 1994; 57: 240–244, [PUBMED], [INFOTRIEVE]
- Yao M., Ohshima K., Suzumiya J., et al. IL-10 and cytotoxic T cell response in EBV associated nasopharyngeal carcinoma. Int. J. Cancer 1997; 72: 398–402, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Fujieda S., Lee K., Sunaga H., et al. Staining of IL-10 predicts clinical outcome in patients with nasopharyngeal carcinoma. Cancer 1999; 85: 1439–1445, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ozyar E., Yildiz F., Akyol F. H., et al. Comparison of AJCC 1988 and 1997 classifications for nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 1999; 44: 1079–1088, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ozyar E., Yildiz F., Akyol F. H., et al. Adjuvant high-dose-rate brachytherapy after external beam radiotherapy in nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2002; 52: 101–108, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Fleming I. D., Cooper J. S., Henson D. E., et al. AJCC Cancer Staging Manual5th ed. Lippincott-Raven, Philadelphia 1997; 31–39
- Shanmugaratnam K., Sobin H. L. The World Health Organization histological classification of tumours of the upper respiratory tract and ear. Cancer 1993; 71: 2689–2697, [PUBMED], [INFOTRIEVE]
- Ayhan A., Yasui W., Yokozaki H., et al. Reduced expression of nm23 protein is associated with tumor stage and distant metastasis in human colorectal carcinomas. Virchows Arch., B Cell. Pathol. 1993; 63: 213–218
- Kaplan E., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958; 53: 457–481, [CSA]
- Cox D. R. Regression models and life tables. J. R. Stat. Soc., B 1972; 34: 187–220, [CSA]
- Wang D., Liebowitz D., Kieff E. An EBV membrane protein expressed in mortalized lymphocytes transforms established rodent cells. Cell 1985; 43: 831–840, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Devergne O., McFarland E. C., Mosialos G., et al. Role of the TRAF binding site and NF-kappa B activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J. Virol. 1998; 72: 7900–7908, [PUBMED], [INFOTRIEVE], [CSA]
- Henderson S., Rowe M., Gregory C., et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein-1 protects infected B cells from programmed cell death. Cell 1991; 65: 1107–1115, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Miller W. E., Earp H. S., Raab-Traub N. The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J. Virol. 1995; 69: 4390–4398, [PUBMED], [INFOTRIEVE], [CSA]
- Klein G. Viral latency and transformation: the strategy of Ebstein Barr virus. Cell 1989; 58: 5–8, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Fahraeus R., Rymo L., Rhim J. S., et al. Morphological transformation of human keratinocytes expressing the LMP gene of Ebstein Barr viruses. Nature 1990; 345: 447–449, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Zheng X., Yuan F., Hu L. Effect of B lymphocyte and NPC derived ABV-LMP1 gene expression on in vitro growth and differentiation of human epithelial cells. Int. J. Cancer 1994; 57: 747–753, [PUBMED], [INFOTRIEVE]
- Pathmanathan R., Prasad U., Sadler R., et al. Clonal proliferation of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N. Engl. J. Med. 1995; 333: 693–698, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ohshima K., Suzumiya J., Tasiro K., et al. EBV infection and associated products in nodal non-Hodgkin' s lymphoma of human immunodeficiency-virus negative Japanese. Am. J. Hematol. 1996; 52: 21–28, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Cortes J. E., Talpaz M., Cabanillas F., et al. Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood 1985; 86: 4702–4704, [CSA]
- Fujieda S., Saito H., Hoshino T. Responses to killer cells in head and neck cancer patients. Eur. Arch. Otorhinolaryngol. 1990; 247: 176–181, [PUBMED], [INFOTRIEVE]
- Young M. R.I., Wright M. A., Lozano Y., et al. Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of cancer. Int. J. Cancer 1996; 67: 333–338, [PUBMED], [INFOTRIEVE]